On May 5, 2026 CiMaas BV reported that it has entered into a research collaboration with East Ocyon Bio, located in Gurugram, Haryana, India, an innovative company dedicated to developing optimally engineered natural killer (NK) cell and gamma delta T cell therapies to cure patients with cancer and autoimmune diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, East Ocyon Bio will start testing the F012 feeder cell line created by CiMaas to support (CAR)-NK cell expansion from peripheral blood. East Ocyon Bio is the first partner in India using F012 feeder cells in their process with peripheral blood derived NK cells and is a validation by others of our techniques. Moreover, it will enable CiMaas to access the Indian market with innovative treatments for cancer patients and autoimmune diseases.

(Press release, CiMaas, MAY 5, 2026, View Source [SID1234665110])